Templeton Emerging Markets (TEI) 10.55 $TEI Templeton

New Post Public Reply Private Reply Replies (0) Message Board

Jun 14, 2016 at 2:19 AM

Templeton Emerging Markets (TEI) 10.55 $TEI

Templeton Emerging Markets Income Fund ("TEI"

Announces Dividend
Marketwired - Tue Mar 15, 9:51AM CDT
Templeton Emerging Markets Income Fund (NYSE: TEI) today announced its quarterly dividend from net investment income of $0.20 per share, payable on April 13, 2016 to shareholders of record on March 30, 2016 (Ex-Dividend Date: March 28, 2016).
TEI: 10.55 (-0.15), BEN: 33.27 (-0.52)

Templeton Releases Closed-End Funds' Portfolio Allocation Updates
Marketwired - Mon Mar 14, 1:28PM CDT
The Templeton closed-end Funds referenced below, which trade on the New York Stock Exchange, today released portfolio allocation updates containing the following information as of February 29, 2016:
TEI: 10.55 (-0.15), BEN: 33.27 (-0.52), EMF: 10.89 (-0.28)

Shares of TEI Down 28.1% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Fri Feb 05, 5:45PM CST
SmarTrend identified a Downtrend for Templeton Emerging Markets Income Fund (NYSE:TEI) on August 6th, 2014 at $13.19. In approximately 18 months, Templeton Emerging Markets Income Fund has returned 28.05% as of today's recent price of $9.49.
TEI: 10.55 (-0.15)

Templeton Emerging Markets Income Fund Has Returned 28.1% Since SmarTrend Recommendation (TEI)
Comtex SmarTrend(R) - Fri Jan 29, 5:05PM CST
SmarTrend identified a Downtrend for Templeton Emerging Markets Income Fund (NYSE:TEI) on August 6th, 2014 at $13.19. In approximately 18 months, Templeton Emerging Markets Income Fund has returned 28.08% as of today's recent price of $9.49.
TEI: 10.55 (-0.15)

31.5% Return Seen to Date on SmarTrend Templeton Emerging Markets Income Fund Call (TEI)
Comtex SmarTrend(R) - Fri Jan 22, 12:30PM CST
SmarTrend identified a Downtrend for Templeton Emerging Markets Income Fund (NYSE:TEI) on August 6th, 2014 at $13.19. In approximately 18 months, Templeton Emerging Markets Income Fund has returned 31.46% as of today's recent price of $9.04.
TEI: 10.55 (-0.15)

Templeton Emerging Markets Income Fund Shares Down 31.5% Since SmarTrend's Sell Call (TEI)
Comtex SmarTrend(R) - Fri Jan 22, 11:34AM CST
SmarTrend identified a Downtrend for Templeton Emerging Markets Income Fund (NYSE:TEI) on August 6th, 2014 at $13.19. In approximately 18 months, Templeton Emerging Markets Income Fund has returned 31.46% as of today's recent price of $9.04.
TEI: 10.55 (-0.15)

Templeton Emerging Markets Income Fund Shares Down 29.0% Since SmarTrend's Sell Call (TEI)
Comtex SmarTrend(R) - Thu Jan 14, 7:20PM CST
SmarTrend identified a Downtrend for Templeton Emerging Markets Income Fund (NYSE:TEI) on August 6th, 2014 at $13.19. In approximately 18 months, Templeton Emerging Markets Income Fund has returned 29.04% as of today's recent price of $9.36.
TEI: 10.55 (-0.15)

Downtrend Call Working As Templeton Emerging Markets Income Fund Stock Falls 24.3% (TEI)
Comtex SmarTrend(R) - Thu Dec 31, 3:53PM CST
SmarTrend identified a Downtrend for Templeton Emerging Markets Income Fund (NYSE:TEI) on August 6th, 2014 at $13.19. In approximately 17 months, Templeton Emerging Markets Income Fund has returned 24.26% as of today's recent price of $9.99.
TEI: 10.55 (-0.15)

Templeton Emerging Markets Income Fund Down 24.2% Since SmarTrend Downtrend Call (TEI)
Comtex SmarTrend(R) - Thu Dec 24, 10:02AM CST
SmarTrend identified a Downtrend for Templeton Emerging Markets Income Fund (NYSE:TEI) on August 6th, 2014 at $13.19. In approximately 17 months, Templeton Emerging Markets Income Fund has returned 24.18% as of today's recent price of $10.00.
TEI: 10.55 (-0.15)

24.2% Return Seen to Date on SmarTrend Templeton Emerging Markets Income Fund Call (TEI)
Comtex SmarTrend(R) - Thu Dec 24, 9:58AM CST
SmarTrend identified a Downtrend for Templeton Emerging Markets Income Fund (NYSE:TEI) on August 6th, 2014 at $13.19. In approximately 17 months, Templeton Emerging Markets Income Fund has returned 24.18% as of today's recent price of $10.00.
TEI: 10.55 (-0.15)

Templeton Emerging Markets Income Fund ("TEI"

Announces Distribution
Marketwired - Tue Dec 01, 9:59AM CST
Templeton Emerging Markets Income Fund (NYSE: TEI) today announced a total distribution of $0.2218, comprised of net investment income of $0.2000 per share and long-term capital gains of $0.0218 per share, payable on December 31, 2015 to shareholders of record on December 16, 2015 (Ex-Dividend Date: December 14, 2015).
TEI: 10.55 (-0.15), BEN: 33.27 (-0.52)

Active Stocks from Diverse Sectors - Research on FARO Technologies, ANI Pharmaceuticals, Templeton Emerging Markets Income Fund, and Chefs Warehouse
ACCESSWIRE - Mon Nov 09, 7:30AM CST
NEW YORK, NY ACCESSWIRE / November 9, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: FARO Technologies Inc. (NASDAQ: FARO), ANI Pharmaceuticals Inc. (NASDAQ: ANIP), Templeton Emerging Markets Income Fund (NYSE: TEI) and Chefs Warehouse Inc. (NASDAQ: CHEF). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
FARO: 35.43 (-0.69), TEI: 10.55 (-0.15), ANIP: 53.19 (+1.14), CHEF: 14.82 (-0.41)

Where Opportunity is Found - Research on KNOT Offshore Partners, Templeton Emerging Markets Income Fund, Anworth Mortgage Asset and BlackRock Floating Rate Income Strategies Fund
ACCESSWIRE - Tue Nov 03, 7:05AM CST
NEW YORK, NY / ACCESSWIRE / November 03, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: KNOT Offshore Partners LP (NYSE: KNOP), Templeton Emerging Markets Income Fund (NYSE: TEI), Anworth Mortgage Asset Corp. (NYSE: ANH) and BlackRock Floating Rate Income Strategies Fund Inc. (NYSE: FRA). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full research reports are being made available to the public on a complimentary basis.
KNOP: 17.67 (-0.54), ANH: 4.66 (-0.07), TEI: 10.55 (-0.15), FRA: 13.25 (-0.23), EMD: 10.70 (-0.09)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

BAIC FOTON Eyes African Market with Strategic Moves

Revving Up for Africa Alright, gearheads and number-crunchers, strap in. BAIC FOTON is making headlines again, and this time they’re zooming right into Africa—like they're claiming pole position on a circuit that's been ignored by many. They’re calling it a “Drive to Great!” but what does that mean for us investors who aren’t just in it for the entertainment?...

RYBREVANT's Promising Results in HNSCC Treatment

Impressive Outcomes for RYBREVANT FASPRO in Head and Neck Cancer Tucked away in the endless cycle of drug trials, a glimmer of hope shines through with new data on RYBREVANT FASPRO in treating head and neck squamous cell carcinoma (HNSCC). This science talk might not rattle the ticker tape directly on NYSE:JNJ, but it has all the makings of a game-changer in the oncology...

Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Dr. Boonipat Inspires Future Women Surgeons at Texas Tech

Sowing Surgical Seeds in Lubbock In Lubbock, Texas, something meaningful unfolded—an event the big market players would hardly blink at, but a significant step for the future of medicine. Led by Dr. Thanapoom "Mo" Boonipat, the founder of FacePlus Plastic Surgery Institute, a unique suturing workshop provided premed students at Texas Tech University hands-on experience...

Gildan Activewear Faces Legal Battle Over Alleged Fraud

Investor Alert: Gildan's Legal Showdown Alright, here's a twist you didn't see coming—or maybe you did if you've been tracking the ticker tapes like a hawk. Gildan Activewear Inc. (NYSE:GIL) is stuck in the kind of hot water that can scald the bottom line. The Stakes: Racing Towards December 14 Marked on your calendar, December 14, is a date of some significance if...

Hims & Hers Faces FTC Heat: Investor Class Action Looms

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Firefox Champions Privacy with Iconic Internet Campaign

Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...

Ivonescimab Promises New Hope for Advanced BTC Patients

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...